Faeth Therapeutics (FTH) Cash from Financing Activities (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Cash from Financing Activities came in at -$1.7 million in Q2 2026, down 901.79% on a YoY basis from $209906.5 in Q2 2025, and down 100.91% quarter-over-quarter from $185.8 million in Q1 2026.
Powered by 
Analysis
Faeth Therapeutics (FTH) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has reported Cash from Financing Activities for 7 consecutive years, with -$1.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Financing Activities fell 901.79% year-over-year to -$1.7 million; the trailing twelve-month figure through Jun 2026 stood at $183.9 million (up 23674.36% YoY), and the FY2025 full-year result was -$645000.0, up 18.04% from the prior year.
- Cash from Financing Activities declined to -$1.7 million in Q2 2026 per FTH's latest filing, from $185.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $185.8 million in Q1 2026 and bottomed at -$7.9 million in Q2 2023.
- Historically, Cash from Financing Activities has averaged $10.7 million across 5 years, with a median of -$199000.0 in 2024.
- The widest YoY moves for Cash from Financing Activities: up 86934.58% in 2026, down 901.79% in 2026.
- Over 5 years, Cash from Financing Activities stood at -$124000.0 in 2022, then plunged by 247.58% to -$431000.0 in 2023, then soared by 54.99% to -$194000.0 in 2024, then soared by 42.78% to -$111000.0 in 2025, then slumped by 1416.22% to -$1.7 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$1.7 million, $185.8 million, and -$111000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -181.51 Mn |
| 10 | Faeth Therapeutics | 218.99 Mn | 218.99 Mn | - | -1.68 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.68 Mn |
| Mar 31, 2026 | 185.83 Mn |
| Dec 31, 2025 | -111,000.00 |
| Sep 30, 2025 | -152,000.00 |
| Jun 30, 2025 | -168,000.00 |
| Mar 31, 2025 | -214,000.00 |
| Dec 31, 2024 | -194,000.00 |
| Sep 30, 2024 | -204,000.00 |
| Jun 30, 2024 | -180,000.00 |
| Mar 31, 2024 | -209,000.00 |
| Dec 31, 2023 | -431,000.00 |
| Sep 30, 2023 | -2.53 Mn |
| Jun 30, 2023 | -7.95 Mn |
| Mar 31, 2023 | -262,000.00 |
| Dec 31, 2022 | -124,000.00 |
| Mar 31, 2022 | 119,000.00 |
| Dec 31, 2021 | -118,000.00 |
| Sep 30, 2021 | -7,000.00 |
| Jun 30, 2021 | -11,000.00 |
| Mar 31, 2021 | 164.08 Mn |